Sage Journals: Discover world-class research

Abstract

Study Design

Retrospective cohort study.

Objectives

The objective of this study was to characterize the association between cell-salvage and allogeneic transfusion rate in pediatric patients undergoing posterior arthrodesis for scoliosis.

Methods

NSQIP Pediatric database years 2016-2022 was used. Patients under the age of 18 who received posterior arthrodesis with 7 or more surgical levels for spinal deformity correction were included. Rates of cell-salvage and allogeneic transfusion were determined. We assessed the impact of cell-salvage on the rate of allogeneic transfusion using chi-square test and multivariable logistic regression.

Results

There were 34,241 patients in this study. The rate of allogeneic transfusion was 21.6% (n = 7407). The allogeneic transfusion rates for idiopathic, neuromuscular, and congenital/syndromic scoliosis were 12.3%, 50.8%, and 25.9%, respectively. Cell-salvage was used in 71.1% of patients (n = 24,344). In the multivariable regression analysis, longer operative time (P < .001), non-idiopathic scoliosis (P < .001), hematocrit less than 35 (P < .001), and ≥13 surgical levels (P < .001) were associated with higher odds of allogeneic transfusion. Use of cell-salvage (P < .001), increasing age (P < .001), and increasing patient weight (P < .001) were associated with significantly lower odds of allogeneic transfusion. In a subanalysis, use of cell-salvage was associated with reduced rate of allogeneic transfusion in patients with idiopathic scoliosis. Cell-salvage was not associated with reduced rates of allogeneic transfusion in neuromuscular and congenital/syndromic scoliosis.

Conclusion

This is the largest study investigating the impact of cell-salvage on rate of allogeneic transfusion in pediatric spinal deformity surgery. Use of cell-salvage is associated with reduced allogeneic transfusion rates in idiopathic scoliosis surgery.

Keywords

pediatric scoliosis spinal deformity transfusion cell salvage risk stratification level II

Introduction

Posterior arthrodesis for scoliosis in pediatric patients is associated with major blood loss from extensive soft tissue dissection and instrumentation of the vertebrae, often necessitating allogeneic blood transfusion.^1-3 Idiopathic scoliosis is the most common type of scoliosis, accounting for up to 85% of cases.⁴ Neuromuscular scoliosis arises from underlying neuromuscular conditions, such as cerebral palsy, muscular dystrophy, and spinal muscular atrophy.⁵ Congenital scoliosis is caused by congenital vertebral anomalies, such as hemivertebra, block vertebra, and unsegmented unilateral bar.⁶ A pooled meta-analysis estimated average blood loss of 500 to 1500cc for adolescent idiopathic scoliosis and 2000 to 3500cc for neuromuscular scoliosis.⁷ Several studies have reported an association between allogeneic blood transfusion and higher infection rates, poor postoperative functional recovery, and reduced long-term survival.^8-10 Consequently, techniques and strategies have evolved to improve blood management to minimize the need for allogeneic blood transfusion.^11,12

Intraoperative cell-salvage involves the collection and processing of blood from the operative field for reinfusion.¹³ Similarly, postoperative cell-salvage collects blood from postsurgical drains for reinfusion.¹² While use of cell-salvage may reduce the need for allogeneic blood transfusion, results have been conflicting.^14-19 The primary aim of this study was to investigate whether the use of cell-salvage in pediatric spinal deformity surgery impacts the rate of allogeneic blood transfusion. The secondary aim was to identify risk factors associated with allogeneic blood transfusion.

Methodology

Source of Data

The American College of Surgeons National Surgical Quality Improvement Program (NSQIP) Pediatric database years 2016 to 2022 was used for this retrospective cohort study. The dataset was harmonized with the procedure targeted spinal fusion dataset. NSQIP is a validated, risk-adjusted, outcomes-based program that measures the quality of surgical care internationally. In each participating hospital, a trained Surgical Clinical Reviewer collects preoperative through 30-day post-operative data on randomly selected patients. Therefore, the database does not record consecutive cases. Data are entered online in a secure, web-based platform available for open access by request.

Participants

Patients under the age of 18 years who received posterior arthrodesis for spinal deformity correction were included in this study. Current Procedural Technology (CPT) codes (CPT 22802 and 22804) and ICD-10 codes (M40, M41, M42, M96, Q67, and Q76) were used to identify the study population. Patients were excluded if they had anterior only approaches for deformity correction or fewer than 7 surgical levels. The NSQIP Pediatric database collection excludes: (1) patients 18 years of age or older, (2) cases involving hyperthermic intraperitoneal chemotherapy, (3) ASA score of 6, (4) concurrent case by different surgical team under the same anesthetic, (5) multiple cases within 30 days, (6) transplant cases, and (7) trauma and abuse cases.

Outcomes of Interest and Statistical Analysis

The primary outcome of this study was receipt of allogeneic blood transfusion within 30-days of surgery. Patient demographics, surgical metrics, volume of allogeneic blood transfusion, and volume of cell-salvage transfusion were characterized using descriptive statistics. Results are presented as means ± standard deviation. The rates of cell-salvage use and allogeneic blood transfusions were reported as proportions. A multivariable logistic regression analysis was performed to identify risk factors associated with allogeneic blood transfusion. Independent variables were chosen a priori based on literature review and clinical relevance. The variables included for adjustment were age in years, weight in pounds, preoperative hematocrit less than 35, type of scoliosis (idiopathic, neuromuscular, and congenital/syndromic), operative time in hours, number of surgical levels (7-12, ≥13 levels), addition of pelvic fixation, use of intraoperative antifibrinolytics, and use of cell-salvage. A secondary analysis was performed in stratified subgroups by type of scoliosis and number of surgical levels. If cell-salvage transfusion is associated with allogeneic transfusion in the regression analysis, a post-hoc chi-square test was performed to compare the rates of postoperative allogeneic transfusion between patients that did and did not receive cell-salvage transfusion.

The alpha value for significance was 0.05 a priori. Listwise deletion was used for missing data for complete case analysis. Statistical analysis was performed using IBM SPSS Statistics version 29.0.2.0.

Results

Participants and Surgical Metrics

There were 34,241 patients included in this study (Table 1). The mean age was 14.1 ± 2.2 years and 68.6% (n = 23,494) were female. Of the 34,241 patients, 67.5% had idiopathic scoliosis (n = 23,106), 19.7% had neuromuscular scoliosis (n = 6736), and 12.8% had congenital/syndromic scoliosis (n = 4399). The mean weight at time of surgery was 115.5 ± 41.6 pounds. The average operative time was 4.9 ± 1.8 hours. There were 58.0% (n = 19,844) that had seven to twelve surgical levels and 42.0% (n = 14,397) that had thirteen or more surgical levels. Pelvic fixation was performed in 0.2% (n = 52) of patients. Intraoperative antifibrinolytics were used in 90.7% (n = 31,046). The only variable with missing data was pre-operative hematocrit, in which 16.8% (n = 5756) was missing.

Table 1.

Summary of Patient Characteristics and Surgical Factors.

	n = 34,241
Age	14.1 ± 2.2 years
Female	68.6% (n = 23 494)
Weight	115.5 ± 41.5 pounds
Type of scoliosis
Idiopathic	67.5% (n = 23,106)
Neuromuscular	19.7% (n = 6736)
Congenital/syndromic	12.8% (n = 4339)
Hematocrit < 35	7.7% (n = 2640)
Surgical factors
Operative time	4.9 ± 1.8 hours
Number of surgical levels
7 to 12 levels	58.0% (n = 19,844)
≥13 levels	42.0% (n = 14,397)
Pelvic fixation	0.2% (n = 52)
Intraoperative antifibrinolytics	90.7% (n = 31,046)
Allogeneic transfusion	21.6% (n = 7407)
Cell-salvage used	71.1% (n = 24,344)

Of the 34,241 patients, 21.6% (n = 7407) received allogeneic blood transfusion. The mean volume of allogeneic blood transfusion was 111.4 ± 274.9 mL (Table 2). Intraoperative allogeneic transfusion and postoperative allogeneic transfusion were used in 16.2% (n = 5542) and 8.5% (n = 2898), respectively. Cell-salvage was used in 71.1% (n = 24,344). The mean volume of cell-salvage transfusion was 178.7 ± 215.7 mL (Table 2). Intraoperative cell-salvage and postoperative cell-salvage were used in 70.6% (n = 24184) and 1.3% (n = 444), respectively. Of the patients that received allogeneic blood transfusion, 26.4% (n = 1958) did not receive cell-salvage transfusion. The mean total transfusion volume, including both cell-salvage and allogeneic blood transfusion, was 290.1 ± 381.1 mL.

Table 2.

Summary of Rate of Transfusion and Transfusion Volumes for Idiopathic, Neuromuscular, and Congenital/Syndromic Scoliosis.

	Rate of Allogeneic Transfusion	Rate of Cell-Salvage Transfusion	Mean Allogenic Transfusion Volume	Mean Cell-Salvage Transfusion Volume	Mean Total Transfusion Volume (Cell-Salvage and Allogeneic)
Idiopathic	12.3% (n = 2843/23106)	70.1% (n = 16190)	56.7 mL	164.0 mL	220.7 mL
Neuromuscular	50.8% (n = 3424/6736)	75.5% (n = 5088)	287.2 mL	225.3 mL	512.5 mL
Congenital/syndromic	25.9% (n = 1140/4399)	69.7% (n = 3066)	129.3 mL	185.0 mL	314.3 mL

Risk Factors for Allogeneic Blood Transfusion and Impact of Cell-Salvage for Entire Cohort

In the multivariable regression analysis, non-idiopathic scoliosis (Neuromuscular: OR = 2.56 [95% CI 2.35-2.79], P < .001; Congenital/syndromic: OR = 1.46 [95% CI 1.32-1.60], P < .001), preoperative hematocrit less than 35 (OR = 2.11 [95% CI 1.91-2.32], P < .001), longer operative time in hours (OR = 1.35 [95% CI 1.33-1.38], P < .001), and higher number of surgical levels (≥13 levels: OR = 1.96, P < .001) were associated with higher odds of allogeneic blood transfusion (Table 3). Higher weight in pounds (OR = 0.99 [95% CI 0.98-0.99], P < .001) and older age in years (OR = 0.97 [95% CI 0.96-0.99], P < .001) were associated with reduced odds of allogeneic blood transfusion. Use of cell-salvage transfusion (OR = 0.81 [95% CI 0.76-0.88], P < .001) was associated with reduced odds of allogeneic blood transfusion (Table 3). Pelvic fixation (P = .505) and use of intraoperative antifibrinolytic administration (P = .903) were not significant variables. Patients who received cell-salvage transfusion had a lower rate of postoperative allogeneic transfusion (8.0% vs 9.7%, X² = 27.5, P < .001).

Table 3.

Multivariable Logistic Regression Analysis for Allogeneic Transfusion for Pediatric Spinal Deformity Surgery.

	Odds Ratio	95% Confidence Interval	P-Value
Age (years)	0.972	[0.958-0.987]	<0.001*
Weight (pounds)	0.987	[0.986-0.988]	<0.001*
Classification (ref. idiopathic)
Neuromuscular	2.559	[2.351-2.786]	<0.001*
Congenital/syndromic	1.457	[1.324-1.602]	<0.001*
Hematocrit<35	2.105	[1.908-2.321]	<0.001*
Operative time (hours)	1.353	[1.327-1.379]	<0.001*
Pelvic fixation	1.254	[0.645-2.439]	0.505
Number of surgical levels (ref. 7-12 levels)	1.960	[1.823-2.106]	<0.001*
Intraoperative antifibrinolytics	0.993	[0.882-1.117]	0.903
Use of cell-salvage	0.814	[0.756-0.876]	<0.001

Secondary Analyses

Idiopathic Scoliosis

There were 23,106 patients with idiopathic scoliosis. The rate of allogeneic blood transfusion was 12.3% (n = 2843) with a mean transfusion volume of 56.7 ± 186.5 mL. Cell-salvage was used in 70.1% (n = 16,190) with a mean transfusion volume of 164.0 ± 192.4 mL. The mean total transfusion volume was 220.7 ± 283.9 mL. In a multivariable logistic regression analysis, use of cell-salvage was associated with significantly reduced rate of allogeneic transfusion in patients with 7-12 surgical levels (OR = 0.82 [95% CI 0.72-0.94], P = .003) and ≥13 surgical levels (OR = 0.61 [95% CI 0.52-0.71], P < .001) (Table 4). Patients who received cell-salvage transfusion had a lower rate of postoperative allogeneic transfusion (4.1% vs 6.2%, X² = 46.7, P < .001).

Table 4.

Multivariable Logistic Regression Analysis for Allogeneic Transfusion for Idiopathic Scoliosis Surgery Stratified by Number of Surgical Levels.

	Odds Ratio	95% Confidence Interval	P-Value
7-12 surgical levels
Age (years)	0.958	[0.928-0.988]	0.007*
Weight (pounds)	0.986	[0.984-0.988]	<0.001*
Hematocrit<35	2.485	[2.108-2.930]	<0.001*
Operative time (hours)	1.447	[1.392-1.504]	<0.001*
Pelvic fixation	-	-	-
Intraoperative antifibrinolytics	0.675	[0.559-0.816]	<0.001*
Use of cell-salvage	0.823	[0.723-0.937]	0.003*
≥13 surgical levels
Age (years)	0.970	[0.937-1.004]	0.084
Weight (pounds)	0.986	[0.984-0.988]	<0.001*
Hematocrit<35	2.054	[1.661-2.540]	<0.001*
Operative time (hours)	1.390	[1.334-1.447]	<0.001*
Pelvic fixation	-	-	-
Intraoperative antifibrinolytics	0.915	[0.706-1.186]	0.503
Use of cell-salvage	0.607	[0.519-0.712]	<0.001*

Neuromuscular Scoliosis

There were 6736 patients with neuromuscular scoliosis. The rate of allogeneic blood transfusion was 50.8% (n = 3424) with a mean transfusion volume of 287.2 ± 414.0 mL. Cell-salvage was used in 75.5% (n = 5088) with a mean transfusion volume of 225.3 ± 267.1 mL. The mean total transfusion volume was 512.5 ± 542.1 mL. In a multivariable logistic regression analysis, use of cell-salvage was not associated with rate of allogeneic transfusion in patients with 7-12 surgical levels (OR = 1.357, P = .07) and ≥13 surgical levels (OR = 0.869, P = .06) (Table 5).

Table 5.

Multivariable Logistic Regression Analysis for Allogeneic Transfusion for Neuromuscular Scoliosis Surgery Stratified by Number of Surgical Levels.

	Odds Ratio	95% Confidence Interval	P-Value
7-12 surgical levels
Age (years)	1.007	[0.948-1.070]	0.816
Weight (pounds)	0.985	[0.979-0.990]	<0.001*
Hematocrit<35	2.466	[1.544-3.937]	<0.001*
Operative time (hours)	1.366	[1.257-1.485]	<0.001*
Pelvic fixation	0.400	[0.033-4.804]	0.470
Intraoperative antifibrinolytics	0.912	[0.578-1.438]	0.692
Use of cell-salvage	1.357	[0.973-1.891]	0.072
≥13 surgical levels
Age (years)	0.976	[0.950-1.003]	0.108
Weight (pounds)	0.990	[0.988-0.992]	<0.001*
Hematocrit<35	1.480	[1.217-1.799]	<0.001*
Operative time (hours)	1.224	[1.184-1.266]	<0.001*
Pelvic fixation	1.021	[0.502-2.075]	0.955
Intraoperative antifibrinolytics	1.819	[1.420-2.330]	<0.001*
Use of cell-salvage	0.869	[0.750-1.007]	0.061

Congenital /Syndromic Scoliosis

There were 4399 patients with congenital or syndromic scoliosis. The rate of allogeneic blood transfusion was 25.9% (n = 1140) with a mean transfusion volume of 129.3 ± 282.4 mL. Cell-salvage was used in 69.7% (n = 3066) with a mean transfusion volume of 185.0 ± 232.3 mL. The mean total transfusion volume was 314.3 ± 393.9 mL. In a multivariable logistic regression analysis, use of cell-salvage was not associated with rate of allogeneic transfusion in patients with 7-12 surgical levels (OR = 0.907, P = .495) and ≥13 surgical levels (OR = 0.819, P = .116) (Table 6).

Table 6.

Multivariable Logistic Regression Analysis for Allogeneic Transfusion for Congenital /Syndromic Scoliosis Surgery Stratified by Number of Surgical Levels.

	Odds Ratio	95% Confidence Interval	P-Value
7-12 surgical levels
Age (years)	0.969	[0.923-1.018]	0.208
Weight (pounds)	0.986	[0.983-0.990]	<0.001*
Hematocrit<35	1.949	[1.352-2.811]	<0.001*
Operative time (hours)	1.509	[1.405-1.619]	<0.001*
Pelvic fixation	-	-	-
Intraoperative antifibrinolytics	0.963	[0.628-1.476]	0.861
Use of cell-salvage	0.907	[0.685-1.201]	0.495
≥13 surgical levels
Age (years)	0.985	[0.939-1.033]	0.538
Weight (pounds)	0.984	[0.981-0.987]	<0.001*
Hematocrit<35	2.841	[2.063-3.914]	<0.001*
Operative time (hours)	1.321	[1.247-1.400]	<0.001*
Pelvic fixation	2.222	[0.155-31.921]	0.557
Intraoperative antifibrinolytics	1.203	[0.790-1.832]	0.390
Use of cell-salvage	0.819	[0.638-1.051]	0.116

Discussion

Posterior arthrodesis for pediatric spinal deformity correction is typically associated with significant blood loss, often requiring allogeneic blood transfusion.²⁰ Techniques and strategies have evolved over the past few decades to optimize blood management to minimize the use of allogeneic transfusion.¹¹ Preoperative strategies include autologous blood donation and red cell augmentation with erythropoietin.¹² Intraoperatively, optimal positioning, hemodilution, hypotensive anesthesia, antifibrinolytics, topical thrombotic agents, and cell salvage are utilized for blood management.¹² However, it remains unclear how effective these strategies are at reducing the rate of allogeneic blood transfusion. The focus of this study was to investigate the impact of cell salvage on the rate of peri-operative allogeneic blood transfusion.

In our study of 34,241 patients, 21.6% received allogeneic blood transfusion. The rate of transfusion in our study was comparable to rates previously reported.^3,11,20 Similar to previous studies investigating risk factors associated with allogeneic blood transfusion,^7,11,20 we found non-idiopathic scoliosis to be associated with a higher rate of allogeneic transfusion, most notably with neuromuscular scoliosis (Idiopathic: 12.3%; Neuromuscular: 50.8%; Congenital/syndromic: 25.9%). Potential reasons for this finding include higher degree of spine curvature, more surgical levels, use of osteotomies for correction, bone quality and longer operative time. However, in our study we found non-idiopathic scoliosis was independently associated with a higher risk of allogeneic blood transfusion when controlling for operative time and number of surgical levels, which were both independently associated with a higher risk of transfusion. Studies have suggested other potential reasons for increased blood loss in neuromuscular scoliosis including osteopenic bone, decreased coagulation factor reserve, altered vascular smooth muscle, and increased fibrinolytic activity.^21-25 These potential underlying mechanisms were beyond the scope of this paper; however, future research to understand the underlying mechanisms for increased blood loss in neuromuscular scoliosis is required to allow for targeted management strategies.

Higher weight in pounds and older age in years were associated with a lower risk of allogeneic transfusion. A study by Rodriguez et al. investigating compensatory reserve index in pediatric patients using a computational algorithm found weight and age to be significant predictive factors for hemodynamic vascular adaptation during acute blood loss.²⁶ They found higher weight to be associated with improved compensatory reserve index, likely due to larger blood volume associated with larger patient size.^26,27 Improved compensatory reserve index with increasing age, independent of blood volume and weight, may be due to improved physiological adaptation mechanisms such as vascular elastic properties, adrenergic response, and pleural/pulmonary pressures.²⁶ We found preoperative hematocrit less than 35 was associated with a higher risk of allogeneic blood transfusion. Similarly, a study by Nuttall et al. identified preoperative hemoglobin concentration as a predictor for allogeneic transfusion.²⁸ Age, weight, and hematocrit are important factors to consider for risk stratification and implementation of additional blood management strategies. Use of erythropoietin and iron supplementation could be considered for preoperative optimization or autologous preoperative blood donation in preparation for surgery in high risk patients.^11,12

Use of intraoperative antifibrinolytics has been widely implemented across various surgical specialities.²⁹ Tranexamic acid and ε-aminocaproic acid are common antifibrinolytic agents used. Multiple studies, systematic reviews, and meta-analyses have reported reduced perioperative blood loss, transfusion rate, and transfusion requirements with use of intraoperative antifibrinolytics in pediatric scoliosis surgery.^29-36 Use of intraoperative antifibrinolytics was not a significant variable in our multivariable logistic regression analysis, except in neuromuscular scoliosis patients with ≥13 surgical levels, in which it was associated with an increased odds of transfusion. The variable in the dataset was collected as a binary variable of whether or not a patient received intraoperative antifibrinolytics. Therefore, it is difficult to draw conclusions based on this dichotomized variable. A study by Farrokhi et al. investigating the impact of a low dose tranexamic acid protocol reported no difference in intraoperative blood loss or blood transfused compared to control.³⁷ In contrast, several studies investigating the more commonly used high dose protocol of 100 mg/kg at the start of surgery followed by 10 mg/kg/hr until skin closure have reported reduced blood loss and transfusion requirements.^33,38,39 To properly study the impact of intraoperative antifibrinolytics, more granular data than this database provides would be required, such as agent, dose, and protocol.

Cell-salvage involves the collection of blood from the operative field for transfusion after appropriate processing to remove cellular, biochemical, and noncellular debris.^12,15 Several studies have reported red blood cell return as high as 60% of red cell loss during surgery.^12,40,41 However, it is unclear when cell-salvage should be utilized since results from various studies have been conflicting.^14-19 Additionally, it can be costly and requires technical personnel to operate.^15,42,43 Therefore, the purpose of our study was to study the utility of cell-salvage in pediatric spine deformity surgery using a large database. Our multivariable logistic regression analysis for the entire study cohort found use of cell-salvage was associated with reduced odds of allogeneic transfusion (OR = 0.814, P < .001). We performed a subanalysis stratified by etiology and number of surgical levels to investigate when cell-salvage may be useful. In our stratified subanalysis, we found use of cell-salvage was associated with reduced odds of allogeneic transfusion in idiopathic scoliosis regardless of number of surgical levels fused. However, use of cell-salvage was not associated with the allogeneic transfusion rate in congenital/syndromic scoliosis or neuromuscular scoliosis. Non-idiopathic scoliosis, particularly neuromuscular scoliosis, has high intraoperative blood loss and is associated with high rates of allogeneic transfusion (Neuromuscular: 50.8%, Congenital/syndromic: 25.9%) and larger transfusion volumes (Neuromuscular: 512.5 mL, Congenital/syndromic: 314.3 mL). The high transfusion requirements for non-idiopathic scoliosis may mean cell-salvage alone cannot prevent the need for allogeneic transfusion. In comparison, idiopathic scoliosis is associated with relatively low blood loss. Our study found a mean total transfusion volume of 220.7 mL. Use of cell-salvage in surgeries with low transfusion requirements, such as idiopathic scoliosis may be adequate to reduce the risk of allogeneic transfusion. Liberal allogeneic transfusion is associated with increased morbidity and cost.^1,44-47 Improved screening for transfusion-transmissible infections and hospital risk reduction protocols have significantly reduced the risk of communicable disease transmission and ABO mismatch (Vitale et al, 2002) (3). However, allogeneic transfusion has been increasingly associated with negative outcomes such as higher rates of infectious complications, non-infectious adverse events, immunological reactions, and poor functions recovery.^1,3,20,45-47 Therefore, use of cell-salvage in idiopathic scoliosis should be considered to reduce the use of allogeneic transfusion and its associated morbidities.

This is the largest study investigating the impact of cell-salvage on rate of allogeneic transfusion in pediatric deformity surgery. We found non-idiopathic scoliosis to have a higher rate of transfusion and require higher transfusion volumes than idiopathic scoliosis. Use of cell-salvage in idiopathic scoliosis was associated with reduced likelihood of allogenic transfusion and should be considered to avoid adverse events associated with allogeneic transfusion. Additional blood management strategies such as preoperative erythropoietin, iron supplementation, and donation should be considered in patients with risk factors for requiring allogeneic transfusion, such as low weight, younger age, and hematocrit <35. This study has limitations. This is a retrospective study using administrative data, which may be susceptible to unmeasured confounding secondary to data elements that were not captured such as pre-operative hemoglobin levels or pre-operative bone density. Additionally, there are likely between-center differences in transfusion rates and use of cell-salvage which we are unable to study or control for using this database. There are various surgical variables that can impact surgical blood loss that could not be studied using the data available, such as increased blood loss associated with osteotomies or resections of congenital vertebral anomalies. The technique used for facetectomies and osteotomies can also impact blood loss; ultrasonic bone cutting devices have been shown to be associated with reduced blood loss compared to other techniques.⁴⁸ Further, we were unable to quantify the association between occurrence of allogeneic transfusion and longer-term outcomes such as pain, delayed complications or readmissions. There are several strengths to this study. This study uses a national registry database with minimal missing data, allowing for more robust statistical power and generalizability. We included a large number of patients with varying scoliosis etiologies, which allowed us to perform a stratified analyses to provide more specific findings to aid in clinical decision making. Future directions include studying the implementation of preoperative optimization protocols in patients with risk factors for requiring allogeneic transfusion and studying the cost-effectiveness of using cell-salvage for idiopathic scoliosis surgery.

Footnotes

Author Contributions

V.K.C. contributed to conceptualization of the project, developing the methodology, analyzing the data, drafting the manuscript, and editing the manuscript. G.S. contributed to conceptualization of the project, developing the methodology, drafting of the manuscript, and editing the manuscript. A.K.M. contributed to developing the methodology and editing the manuscript. D.E.L. contributed to editing the manuscript. D.L.S. contributed to conceptualization of the project, developing the methodology, and editing the manuscript.

Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: V.K.C., G.S., A.K.M., and D.E.L. declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. D.L.S. is a consultant for Highridge and Globus Medical and receives royalties from Medtronic, Highridge, Globus Medical, and Wolters Fluwer Health.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethical Statement

ORCID iD

Vivien Chan

References

Fercho

Krakowiak

Yuser

, et al. The incidence and risk factors for allogeneic blood transfusions in pediatric spine surgery: national data. Healthcare. 2023;11(4):533.

Fernandes

Soares do Brito

Flores

Monteiro

. Blood management and risk assessment for transfusion in pediatric spinal deformity surgery. Adv Hematol. 2020;2020(1):8246309.

Yoshihara

Yoneoka

. Predictors of allogeneic blood transfusion in spinal fusion for pediatric patients with idiopathic scoliosis in the United States, 2004–2009. Spine. 2014;39(22):1860-1867.

Horne

Flannery

Usman

. Adolescent idiopathic scoliosis: diagnosis and management. Am Fam Physician. 2014;89(3):193-198.

Reames

Smith

K-MG

, et al. Complications in the surgical treatment of 19,360 cases of pediatric scoliosis: a review of the scoliosis research society morbidity and mortality database. Spine. 2011;36(18):1484-1491.

Weinstein

. The Pediatric Spine: Principles and Practice. Philadelphia: Lippincott Williams & Wilkins; 2001.

Shapiro

Sethna

. Blood loss in pediatric spine surgery. European Spine Journal. 2005;Suppl 1:6-17.

Engoren

Habib

Hadaway

, et al. The effect on long-term survival of erythrocyte transfusion given for cardiac valve operations. Ann Thorac Surg. 2009;88(1):95-100.

Murphy

Reeves

Rogers

Rizvi

Culliford

Angelini

. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation. 2007;116(22):2544-2552.

10.

Spahn

Moch

Hofmann

Isbister

. Patient blood management: the pragmatic solution for the problems with blood transfusions. The Journal of the American Society of Anesthesiologists. 2008;109(6):951-953.

11.

Vitale

Levy

Park

Choi

Choe

Roye

. Quantifying risk of transfusion in children undergoing spine surgery. Spine J. 2002;2(3):166-172.

12.

Kuklo

Owens

Polly

. Perioperative blood and blood product management for spinal deformity surgery. Spine J. 2003;3(5):388-393.

13.

Cheriyan

Dua

Goldstein

Errico

Kumar

. Efficacy of intraoperative cell salvage in spine surgery: a meta-analysis. J Neurosurg Spine. 2020;33(2):261-269.

14.

Weiss

Skaggs

Tanner

Tolo

. Cell saver: is it beneficial in scoliosis surgery? J Child Orthop. 2007;1(4):221-227.

15.

Bowen

Gardner

Scaduto

Eagan

Beckstead

. Efficacy of intraoperative cell salvage systems in pediatric idiopathic scoliosis patients undergoing posterior spinal fusion with segmental spinal instrumentation. Spine. 2010;35(2):246-251.

16.

Miao

Y-L

H-S

Guo

W-Z

, et al. The efficacy and cost-effectiveness of cell saver use in instrumented posterior correction and fusion surgery for scoliosis in school-aged children and adolescents. PLoS One. 2014;9(4):e92997.

17.

Akgul

Dikici

Ekinci

Buget

Polat

Sar

. The efficacy of cell saver method in the surgicaltreatment of adolescent idiopathic scoliosis. Acta Orthop Traumatol Turcica. 2014;48(3):303-306.

18.

Ersen

Ekıncı

Bılgıc

Kose

Oguz

Sehırlıoglu

. Posterior spinal fusion in adolescent idiopathic scoliosis with or without intraoperative cell salvage system: a retrospective comparison. Musculoskelet Surg. 2012;96:107-110.

19.

Liang

Shen

Chua

, et al. Does intraoperative cell salvage system effectively decrease the need for allogeneic transfusions in scoliotic patients undergoing posterior spinal fusion? A prospective randomized study. Eur Spine J. 2015;24:270-275.

20.

Michelet

Julien-Marsollier

Hilly

Diallo

Vidal

Dahmani

. Predictive factors of intraoperative cell salvage during pediatric scoliosis surgery. Cell saver during scoliosis surgery in children. Anaesth Crit Care Pain Med. 2018;37(2):141-146.

21.

Winter

Kriel

Novacheck

Luxenberg

Leutgeb

Erickson

. Perioperative blood loss: the effect of valproate. Pediatr Neurol. 1996;15(1):19-22.

22.

Miyatake

Miike

Zhao

Yoshioka

Uchino

Usuku

. Possible systemic smooth muscle layer dysfunction due to a deficiency of dystrophin in duchenne muscular dystrophy. J Neurol Sci. 1989;93(1):11-17.

23.

Noordeen

Haddad

Muntoni

Gobbi

Hollyer

Bentley

. Blood loss in duchenne muscular dystrophy: vascular smooth muscle dysfunction? J Pediatr Orthop B. 1999;8(3):212-215.

24.

Saito

Takenaka

Miyai

, et al. Coagulation and fibrinolysis disorder in muscular dystrophy. Muscle Nerve. 2001;24(3):399-402.

25.

Edler

Murray

Forbes

. Blood loss during posterior spinal fusion surgery in patients with neuromuscular disease: is there an increased risk? Paediatr Anaesth. 2003;13(9):818-822.

26.

Rodriguez

Morgan

Lara

Zablah

. Baseline values of the compensatory reserve index in a healthy pediatric population. Pediatr Cardiol. 2022;43(2):344-349.

27.

Muraki

Hiraoka

Nagata

, et al. Novel method for estimating the total blood volume: the importance of adjustment using the ideal body weight and age for the accurate prediction of haemodilution during cardiopulmonary bypass. Interact Cardiovasc Thorac Surg. 2018;27(6):802-807.

28.

Nuttall

Horlocker

Santrach

Oliver

Dekutoski

Bryant

. Predictors of blood transfusions in spinal instrumentation and fusion surgery. Spine. 2000;25(5):596-601.

29.

Karimi

Nambiar

Phan

Ambikaipalan

Mobbs

. Antifibrinolytic agents for paediatric scoliosis surgery: a systematic review and meta-analysis. Eur Spine J. 2019;28:1023-1034.

30.

Aghajanian

Mohammadifard

Kohandel Gargari

Naeimi

Bahadorimonfared

Elsamadicy

. Efficacy and utility of antifibrinolytics in pediatric spine surgery: a systematic review and network meta-analysis. Neurosurg Rev. 2024;47(1):177.

31.

Grant

Howard

Luntley

Harder

Aleissa

Parsons

. Perioperative blood transfusion requirements in pediatric scoliosis surgery: the efficacy of tranexamic acid. J Pediatr Orthop. 2009;29(3):300-304.

32.

Yuan

Q-M

Zhao

Z-H

B-S

. Efficacy and safety of tranexamic acid in reducing blood loss in scoliosis surgery: a systematic review and meta-analysis. Eur Spine J. 2017;26:131-139.

33.

Newton

Bastrom

Emans

, et al. Antifibrinolytic agents reduce blood loss during pediatric vertebral column resection procedures. Spine. 2012;37(23):E1459-E1463.

34.

Tzortzopoulou

Cepeda

Schumann

Carr

. Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children. Cochrane Database Syst Rev. 2008;16(3):CD006883.

35.

Gill

Chin

Levin

Feng

. The use of antifibrinolytic agents in spine surgery: a meta-analysis. J Bone Joint Surg Am. 2008;90(11):2399-2407.

36.

Florentino-Pineda

Blakemore

Thompson

Poe-Kochert

Adler

Tripi

. The effect of ε-aminocaproic acid on perioperative blood loss in patients with idiopathic scoliosis undergoing posterior spinal fusion: a preliminary prospective study. Spine. 2001;26(10):1147-1151.

37.

Farrokhi

Kazemi

Eftekharian

Akbari

. Efficacy of prophylactic low dose of tranexamic acid in spinal fixation surgery: a randomized clinical trial. J Neurosurg Anesthesiol. 2011;23(4):290-296.

38.

Dhawale

Shah

Sponseller

, et al.

Are antifibrinolytics helpful in decreasing blood loss and transfusions during spinal fusion surgery in children with cerebral palsy scoliosis?

Spine. 2012;37(9):E549-E555.

39.

Shapiro

Zurakowski

Sethna

. Tranexamic acid diminishes intraoperative blood loss and transfusion in spinal fusions for duchenne muscular dystrophy scoliosis. Spine. 2007;32(20):2278-2283.

40.

Mann

Wilham

Brower

Nash

. Decreasing homologous blood transfusion in spinal surgery by use of the cell saver and predeposited blood. Spine. 1989;14(12):1296-1300.

41.

Sculco

. Blood management in orthopedic surgery. Am J Surg. 1995;170(6):S60-S63.

42.

Siller

Dickson

Erwin

. Efficacy and cost considerations of intraoperative autologous transfusion in spinal fusion for idiopathic scoliosis with predeposited blood. Spine. 1996;21(7):848-852.

43.

Slagis

Benjamin

Volz

Giordano

. Postoperative blood salvage in total hip and knee arthroplasty. A randomised controlled trial. J Bone Joint Surg Br. 1991;73(4):591-594.

44.

Purvis

Goodwin

De la Garza-Ramos

, et al. Effect of liberal blood transfusion on clinical outcomes and cost in spine surgery patients. Spine J. 2017;17(9):1255-1263.

45.

Oakley

Woods

Arnold

Young

. Transfusion reactions in pediatric compared with adult patients: a look at rate, reaction type, and associated products. Transfusion. 2015;55(3):563-570.

46.

Stainsby

Jones

Wells

Gibson

Cohen

SHOT Steering Group . Adverse outcomes of blood transfusion in children: analysis of UK reports to the serious hazards of transfusion scheme 1996–2005. Br J Haematol. 2008;141(1):73-79.

47.

Lavoie

. Blood transfusion risks and alternative strategies in pediatric patients. Paediatr Anaesth. 2011;21(1):14-24.

48.

Renjith

Eamani

Raja

Shetty

. Ultrasonic bone scalpel in spine surgery. J Orthop. 2023;41:1-7.

Can Intra-Operative Cell Salvage Reduce the Rate of Allogeneic Transfusion in Pediatric Spinal Deformity Surgery?

Abstract

Study Design

Objectives

Methods

Results

Conclusion

Keywords

Introduction

Methodology

Source of Data

Participants

Outcomes of Interest and Statistical Analysis

Results

Participants and Surgical Metrics

Risk Factors for Allogeneic Blood Transfusion and Impact of Cell-Salvage for Entire Cohort

Secondary Analyses

Idiopathic Scoliosis

Neuromuscular Scoliosis

Congenital /Syndromic Scoliosis

Discussion

Footnotes

Author Contributions

Declaration of Conflicting Interests

Funding

Ethical Statement

ORCID iD

References